The biotechnology company Cassava Sciences failed on Wednesday to end a malicious prosecution lawsuit by doctors and ...

Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in ...

Cassava Sciences, Inc.’s SAVA share price has dipped by 20.00%, which has investors questioning if this is right time to buy.

The heavy selling pressure might have exhausted for Cassava Sciences (SAVA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ...

While Cassava is stopping investigations into simufilam in Alzheimer’s disease, the therapy is now being evaluated in ...

Cassava Sciences faces a significant setback after announcing its drug Simufilam failed to achieve meaningful results in the ...

Cassava Sciences is ending simufilam development for Alzheimer's after Phase 3 trials failed. The company is shifting focus to potential seizure treatments.

Cassava Sciences has given up on simufilam in Alzheimer’s disease. | Cassava Sciences has given up on simufilam in ...

SAVA opened at $1.75 on Tuesday. Cassava Sciences has a 52 week low of $1.74 and a 52 week high of $42.20. The business has a 50 day moving average price of $2.53 and a two-hundred day moving ...

Cassava Sciences said on Tuesday its Alzheimer's drug simufilam, which has been at the center of regulatory scrutiny, failed in a second late-stage study, sending shares of the company down 20% in ...

We are disappointed that the results of REFOCUS-ALZ and RETHINK-ALZ showed no treatment benefit for patients with mild-to-moderate Alzheimer’s ...

Cassava Sciences will discontinue its potential Alzheimer's treatment after recent trials showed no improvement to cognitive or functional decline. Shares halted from trading ahead of the morning bell ...